Zeposia’s Ulcerative Colitis Approval Provides BMS’s Beachhead Into GI
The second US approval for the S1P receptor agonist brings Bristol into the gastrointestinal space, and is just the starting point for the pharma in that arena, the company told Scrip.
You may also be interested in...
Remission rates with existing therapies leave much room for improvement, so a variety of treatments are needed – leaving major players attempting to carve unique paths in a crowded market.
The ulcerative colitis and Crohn’s disease landscapes may shift soon but new drugs will compete with entrenched blockbusters, including Humira, Stelara and Entyvio, with biosimilars on the way.
The company will present detailed data in the future, but top-line results show statistically significant improvement over placebo at 12 weeks in ulcerative colitis, an increasingly competitive market.